Searched for
ERIS LIFESCIENCES ACQUISITIONS
Eris Lifesciences reports 41% year-on-year rise in net profit in Q1Eris Lifesciences reported a robust 41% YoY increase in net profit, reaching Rs 125 crore for the first quarter, driven by strong performan...- Eris Lifesciences net profit drops 4.5% to Rs 89 crore in Q1FY25Eris acquired Biocon Biologics' domestic branded formulation business for Rs 1,242 crore in Q4FY24 and dermatology and nephrology units in ...
- Eris Lifesciences Q1 Results: Net dips 4.5% YoY at Rs 89 croreEris Lifesciences on Friday said its consolidated profit after tax declined by 4.5 per cent year on year to Rs 89 crore for the quarter end...
- Eris Lifesciences acquires Biocon Biologics domestic branded formulation business for Rs 1,242 croreAs part of the deal over 430 employees associated with the business are expected to transition to Eris, ensuring continuity for both employ...
- Eris acquires 51 pc stake in Swiss Parenterals for Rs 637.5 crEris Lifesciences on Tuesday said it has acquired a 51 per cent stake in Swiss Parenterals for Rs 637.5 crore. Ahmedabad-based Swiss Parent...
- Eris Lifesciences acquires Biocon Biologics' nephro, derma units for Rs 366 croreEris Lifesciences has announced that it has reached a definitive agreement to acquire the dermatology and nephrology branded formulations b...
- Eris Lifesciences acquires 9 dermatology brands from Dr Reddy's for Rs 275 crThe transaction will be financed through borrowings and will achieve financial closure in the next few days, the drug firm said. In a separ...
- Dr Reddy's sells cosmetic derma brands to Eris for Rs 275 crore“India is a focus market for us. We aspire to break into the top 5 in India," said M.V. Ramana, CEO – Branded Markets (India & Emerging Mar...
- Buy Eris Lifesciences, target price Rs 780: Motilal Oswal Financial ServicesEris Lifesciences, incorporated in the year 2007, is a Mid Cap company (having a market cap of Rs 8701.37 Crore) operating in Pharmaceutica...
- Eris buys nine derma brands from Glenmark for Rs 340 croreThe nine brands have sales of Rs 87.30 crores for FY22, which represents valuation of 3.9x of the sales of these brands in FY22. The acquir...
- Eris Lifesciences scouting for acquisitions to diversify bizThrough acquisition of Strides domestic formulations portfolio in 2017, Eris Lifesciences got a toehold in the neurology and psychiatry seg...
- Eris Lifesciences enters licensing deal with Biocon for insulin glargineThe launch of long acting insulin glargine will help Eris to fill the gap in its insulin portfolio. Eris derives more than half of its reve...
- Eris acquires Oaknet Healthcare for Rs 650 crore to gain foothold in derma segmentThe drug maker said the acquisition will be completed by way of a share purchase agreement as a result of which Oaknet will become a wholly...
- Analyst Calls: Info Edge, Eris Lifesciences, Essel PropackAntique Stock Broking has initiated coverage on Essel Propack with a target price of ₹240.
- Accumulate Eris Lifesciences, target Rs 704: Prabhudas LilladherAccumulate Eris Lifesciences Ltd. at a price target of Rs 704.
- Eris Lifesciences, Shasun Strides shares rise on Rs 500 crore dealThe India branded generics business being divested by Strides had sales of Rs 181 core FY 2017, the statement said.
- Eris signs definitive pact to buy Strides’ India portfolio for Rs 500 crThe acquisition is Eris’s fourth and the largest buyout in the last 18 months. With this, the company will be among the top ten companies i...
- Eris Lifesciences IPO sails through; oversubscribed 3 timesThe public offer received bids for 1.34 crore shares against the total issue size of 1.59 crore shares.
- Eris Lifesciences IPO off to slow start; should you subscribe?The company has plans to raise Rs 1732-1741 crore from the equity market at a price band of Rs 600-603 per equity share.
- Should you invest in Eris Lifesciences?Despite being expensive, the issue holds a compelling investment proposition.
Load More
